Nephrogen’s® Biomarker Detection Platform offers a rapid, inexpensive, and non-invasive method of detecting acute kidney injury in its early stages.

 

 
                NON-INVASIVE   The test will be conducted with either a small urine or blood sample. There is no need for incisions or biopsies. 

              NON-INVASIVE

The test will be conducted with either a small urine or blood sample. There is no need for incisions or biopsies. 

                           INEXPENSIVE   Nephrogen’s® platform will be sold to hospitals, doctor’s offices, and outpatient clinics as a diagnostic test for AKI in urine and blood samples and reimbursed through CMS and private payers. 

                         INEXPENSIVE

Nephrogen’s® platform will be sold to hospitals, doctor’s offices, and outpatient clinics as a diagnostic test for AKI in urine and blood samples and reimbursed through CMS and private payers. 

                       RAPID   Nephrogen's detection platform has the industry's fastest turnover times for acute kidney injury. The test takes 30 minutes to run from start to finish.

                     RAPID

Nephrogen's detection platform has the industry's fastest turnover times for acute kidney injury. The test takes 30 minutes to run from start to finish.

 

Physicians are currently unable to detect and diagnose many common deadly diseases until after it is too late to treat them. For example, AKI incidence is believed to be similar to that of myocardial infarction but is often silent and goes undetected until after the patient has lost nearly all kidney function. AKI is often detected through a tissue biopsy, which is a heavily invasive procedure can cause internal bleeding and lead to additional clinical complications that only further harm the patient. If detected early, there can be intervention to minimize functional loss from AKI, but there are currently no early, non-invasive detection methods for AKI.


The New Technology

Our detection platform will focus on the urine and blood biomarkers, KIM-1 (kidney injury molecule-1) and NGAL (neutrophil gelatinase-associated lipocalin). Due to its ability to quantitatively and sensitively measure biomarker concentrations, the platform can be expanded to other diseases too and will work especially well for diseases with biomarkers that require a quantitative readout or personalized cut-off values. The platform can also eliminate the need for harmful and painful invasive procedures such as biopsies.

Founder, Demetri Maxim, talks about how he got started on the project that eventually became Nephrogen as we know it today. 


Investors and Partnerships